Trial Profile
Improvement of exercise tolerance by a long-term assisting use of the short acting beta 2 agonist (procaterol) for pulmonary rehabilitation in patients with COPD.
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 May 2016
Price :
$35
*
At a glance
- Drugs Procaterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 22 Jan 2013 New trial record